One in 35 myocardial injury
July 26, 2023
1,701,617
80,213
16,138
5.66%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around July 26, 2023
See what was published immediately before and after this episode.
18:10Now PlayingOne in 35 myocardial injury
YouTube Description
as posted by the channelMyocardial Injury after COVID-19 mRNA-1273 Booster Vaccination
Department of Cardiology and Cardiovascular Research Institute Basel
(ESC Heart Failure, open-access journal of the Heart Failure Association of the European Society of Cardiology)
Prospective active surveillance study
(Not a retrospective passive surveillance study)
Industry independent, instigated by the investigators
Aims
Incidence and potential mechanisms of oligosymptomatic myocardial injury,
following COVID-19 mRNA booster vaccination.
Safety net for those already boosted,
screening and prevention of complications
Methods and Results
December 2021 to February 2022
Hospital employees scheduled to undergo mRNA-1273 booster vaccination,
assessed for mRNA-1273 vaccination-associated myocardial injury,
defined as acute dynamic increase in high-sensitivity cardiac troponin T (hs-cTnT) concentration,
above the sex-specific upper-limit of normal on day 3 (48-96h)
after vaccination without evidence of an alternative cause.
777 participants
Median age 37 years, 69.5% women
40 participants (5.1%) had elevated high-sensitivity cardiac troponin T concentration on day 3
(Taken as above the 99th percentile for age and sex)
mRNA-1273 vaccine-associated myocardial injury was adjudicated in 22 participants (2.8%).
One in 35 recipients (2.8%) had vaccine-associated myocardial injury
Of the 777, 2 women had chest pain
Of these 22 cases with mRNA-1273 vaccine-associated myocardial injury
Twenty cases occurred in women
Two in men
Hs-cTnT-elevations were mild and only temporary.
No patient had ECG- changes,
none developed major adverse cardiac events within 30 days
In the overall booster cohort
hs-cTnT concentrations, on day 3
Median 5 ng/L, IQR, 4-6
Matched controls (n=777), 3 ng/L IQR, 3-5
Significantly higher p less than 0.001
(If elevated on day3, given warning, investigations and advice)
No MACE (major adverse cardiac events) within 30 days
Cases had comparable systemic reactogenicity
Concentrations of cytokines and cytokine antagonists were markers quantifying systemic inflammation
Lower concentrations
GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) induces the development of monocytes, neutrophils, eosinophils, and myeloid and dermal dendritic cells.
IFN- λ1(IL-29) a group of anti-viral cytokines, that consists of four IFN-λ molecules
Conclusion
mRNA-1273 vaccine-associated myocardial injury was more common than previously thought,
being mild and transient,
and more frequent in women versus men.
The possible protective role of IFN-λ1(IL-29) and GM-CSF warrant further studies.
Similar Pfizer studies
A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons
A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons
NZ Pfizer add
New hope children centre
If you would like to support the work in Africa, donations are welcome using the PayPal link below. 100% of funds go directly to Africa. Thank you.
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.